Maartens G - Search Results

1

High prevalence of subtherapeutic plasma concentrations of efavirenz in children.

Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. Ren Y, et al. Among authors: maartens g. J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):133-6. doi: 10.1097/QAI.0b013e31805c9d52. J Acquir Immune Defic Syndr. 2007. PMID: 17417100 Clinical Trial.

2

Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis.

Wood R, Maartens G, Lombard CJ. Wood R, et al. Among authors: maartens g. J Acquir Immune Defic Syndr. 2000 Jan 1;23(1):75-80. doi: 10.1097/00126334-200001010-00010. J Acquir Immune Defic Syndr. 2000. PMID: 10708059

3

Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area.

Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. Badri M, et al. Among authors: maartens g. Int J Tuberc Lung Dis. 2001 Mar;5(3):225-32. Int J Tuberc Lung Dis. 2001. PMID: 11326821

4

Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa.

Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E. Coetzee D, et al. Among authors: maartens g. AIDS. 2004 Apr 9;18(6):887-95. doi: 10.1097/00002030-200404090-00006. AIDS. 2004. PMID: 15060436 Free article.

5

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F. Sanne I, et al. Among authors: maartens g. J Infect Dis. 2005 Mar 15;191(6):825-9. doi: 10.1086/428093. Epub 2005 Feb 10. J Infect Dis. 2005. PMID: 15717255 Clinical Trial.

6

Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.

McIlleron H, Meintjes G, Burman WJ, Maartens G. McIlleron H, et al. Among authors: maartens g. J Infect Dis. 2007 Aug 15;196 Suppl 1:S63-75. doi: 10.1086/518655. J Infect Dis. 2007. PMID: 17624828 Review.

7

Is it safe to switch between efavirenz and nevirapine in the event of toxicity?

Mehta U, Maartens G. Mehta U, et al. Among authors: maartens g. Lancet Infect Dis. 2007 Nov;7(11):733-8. doi: 10.1016/S1473-3099(07)70262-1. Lancet Infect Dis. 2007. PMID: 17961859 Review.

8

Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.

Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, Maartens G. Cohen K, et al. Among authors: maartens g. J Antimicrob Chemother. 2008 Feb;61(2):389-93. doi: 10.1093/jac/dkm484. Epub 2007 Dec 19. J Antimicrob Chemother. 2008. PMID: 18096560

9

Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.

Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. Ren Y, et al. Among authors: maartens g. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):566-9. doi: 10.1097/QAI.0b013e3181642257. J Acquir Immune Defic Syndr. 2008. PMID: 18197120

10

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.

Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G. Boulle A, et al. Among authors: maartens g. JAMA. 2008 Aug 6;300(5):530-9. doi: 10.1001/jama.300.5.530. JAMA. 2008. PMID: 18677025

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

403 results

Search Page

Filters